What companies or researchers are associated with the term memoblast?

1. Two separate clusters: biotech Mesoblast vs. consumer “MemoBlast”

Search results clearly split into two clusters. One cluster centers on Mesoblast Limited, an ASX/Nasdaq‑listed company developing allogeneic mesenchymal stromal cell therapies with recent press activity and FDA interactions (company site, press releases, coverage of meetings and commercial results) ^{[1] [5] [6]}. The other cluster contains consumer‑oriented memory‑supplement websites using the name MemoBlast or memoblast.co and reviews that flag trust or scam concerns ^{[2] [3] [4]}.

2. Mesoblast: corporate actor with recent clinical and commercial headlines

Mesoblast appears across investor and media notices: the company’s investor site, participation at investor conferences, an FDA meeting about rexlemestrocel‑L for opioid cessation in chronic low back pain, and reporting of Ryoncil (remestemcel‑L‑rknd) revenues and FDA approval for pediatric GvHD are all in the file set ^{[1] [5] [7] [6]}. Those items identify Mesoblast as a commercial and research organization — not as a person or academic researcher connected to the specific token "memoblast" beyond sharing a similar string of letters ^{[1] [6]}.

3. MemoBlast / memoblast.co: consumer supplement branding, questionable trust scores

Several domain pages use MemoBlast as a memory‑enhancement supplement brand and advertise “scientifically‑backed” natural ingredients and cognitive benefits ^{[2] [8]}. Independent site‑review services evaluated memoblast.co and gave mixed or low trust scores: Gridinsoft assigned a 59/100 trust score and Scam Detector flagged memoblast.co with a low score and recommended against it ^{[3] [4]}. Those pages are commercial and third‑party review content, not peer‑reviewed research ^{[2] [4]}.

4. No researcher names or academic groups tied to the term "memoblast" in these results

None of the supplied sources names individual researchers, laboratories, or academic institutions that coin, define, or publish under the single label "memoblast." Sources either treat the string as part of the corporate name Mesoblast or as a consumer product domain/brand MemoBlast ^{[1] [2]}. Therefore, claims that a particular scientist or research group is “the memoblast” originator are not supported by the available reporting.

5. Possible sources of confusion and implicit agendas

The similarity between “Mesoblast” (a high‑profile biotech firm) and “MemoBlast/memoblast.co” (memory supplement branding) creates an easy confusion for lay readers or automated crawlers; commercial supplement operators may leverage scientific language to appear credible, while Mesoblast’s press emphasises regulatory milestones and revenue for investors ^{[5] [2]}. The supplement sites have a clear commercial agenda to sell products; the review sites’ negative assessments indicate consumer‑protection motives ^{[2] [4]}.

6. How to verify further (limitations of current reporting)

Available sources are limited to press releases, investor pages, consumer product pages and site‑review sites; none are peer‑reviewed scientific publications or trademark registries that would definitively map the term to a researcher or registered brand owner. For authoritative confirmation of ownership or origin of the term "memoblast," consult trademark databases, academic literature searches (PubMed/Google Scholar), or corporate filings — none of which are present in the supplied results (not found in current reporting).

7. Bottom line for readers and next steps

If you encountered "memoblast" in a research or clinical context, treat it as ambiguous: it is not shown here as a scholarly term but rather as part of corporate or commercial branding (Mesoblast; MemoBlast) ^{[1] [2]}. If you want a definitive attribution (researcher name, paper, or trademark), provide a source link or allow a targeted search of academic/trademark databases; the sources supplied do not contain that definitive attribution (not found in current reporting).